Reference : Testing association of rare genetic variants with resistance to three common antiseiz...
Scientific journals : Article
Human health sciences : Neurology
Systems Biomedicine
Testing association of rare genetic variants with resistance to three common antiseizure medications
Wolking, Stefan [> >]
Moreau, Claudia [> >]
Nies, Anne T. [> >]
Schaeffeler, Elke [> >]
McCormack, Mark [> >]
Auce, Pauls [> >]
Avbersek, Andreja [> >]
Becker, Felicitas [> >]
Krenn, Martin [> >]
Møller, Rikke S. [> >]
Nikanorova, Marina [> >]
Weber, Yvonne G. [> >]
Weckhuysen, Sarah [> >]
Cavalleri, Gianpiero L. [> >]
Delanty, Norman [> >]
Depondt, Chantal [> >]
Johnson, Michael R. [> >]
Koeleman, Bobby P. C. [> >]
Kunz, Wolfram S. [> >]
Marson, Anthony G. [> >]
Sander, Josemir W. [> >]
Sills, Graeme J. [> >]
Striano, Pasquale [> >]
Zara, Federico [> >]
Zimprich, Fritz [> >]
Schwab, Matthias [> >]
Krause, Roland mailto [University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) >]
Sisodiya, Sanjay M. [> >]
Cossette, Patrick [> >]
Girard, Simon L. [> >]
Lerche, Holger [> >]
EpiPGX Consortium [> >]
Yes (verified by ORBilu)
[en] epilepsy ; drugs ; genomics
[en] Abstract Objective Drug resistance is a major concern in the treatment of individuals with epilepsy. No genetic markers for resistance to individual antiseizure medication (ASM) have yet been identified. We aimed to identify the role of rare genetic variants in drug resistance for three common ASMs: levetiracetam (LEV), lamotrigine (LTG), and valproic acid (VPA). Methods A cohort of 1622 individuals of European descent with epilepsy was deeply phenotyped and underwent whole exome sequencing (WES), comprising 575 taking LEV, 826 LTG, and 782 VPA. We performed gene- and gene set–based collapsing analyses comparing responders and nonresponders to the three drugs to determine the burden of different categories of rare genetic variants. Results We observed a marginally significant enrichment of rare missense, truncating, and splice region variants in individuals who were resistant to VPA compared to VPA responders for genes involved in VPA pharmacokinetics. We also found a borderline significant enrichment of truncating and splice region variants in the synaptic vesicle glycoprotein (SV2) gene family in nonresponders compared to responders to LEV. We did not see any significant enrichment using a gene-based approach. Significance In our pharmacogenetic study, we identified a slightly increased burden of damaging variants in gene groups related to drug kinetics or targeting in individuals presenting with drug resistance to VPA or LEV. Such variants could thus determine a genetic contribution to drug resistance.
European Commission - EC
Researchers ; Professionals
FP7 ; 279062 - EPIPGX - Epilepsy Pharmacogenomics: delivering biomarkers for clinical use

File(s) associated to this reference

Fulltext file(s):

Open access
Wolking_et_al-2020-Epilepsia.pdfPublisher postprint998.68 kBView/Open

Bookmark and Share SFX Query

All documents in ORBilu are protected by a user license.